WallStSmart
CRVS

Corvus Pharmaceuticals Inc

NASDAQ: CRVS · HEALTHCARE · BIOTECHNOLOGY

$12.56
+5.46% today

Updated 2026-06-22

Market cap
$1.00B
P/E ratio
P/S ratio
EPS (TTM)
$-0.55
Dividend yield
52W range
$4 – $27
Volume
1.6M

Corvus Pharmaceuticals Inc (CRVS) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item201420152016201720182019202020212022202320242025
Operating cash flow$-104727.00$-11.33M$-27.86M$-46.21M$-40.99M$-37.32M$-34.78M$-36.72M$-27.02M$-23.93M$-25.42M$-32.80M
Capital expenditures$1.75M$1.75M$2.20M$266000.00$355000.00$25000.00$76000.00$5000.00$269000.00$34000.00$0.00$174000.00
Depreciation
Stock-based comp$428000.00$3.83M$6.23M$7.13M$7.35M$5.75M$4.23M$2.69M$2.15M$3.00M$5.33M
Free cash flow$-1.85M$-13.07M$-30.06M$-46.48M$-41.34M$-37.35M$-34.85M$-36.72M$-27.29M$-23.97M$-25.42M$-32.97M
Investing cash flow
Financing cash flow
Dividends paid$0.00$0.00
Share repurchases
Debt repayment
Net change in cash$945000.00$40.06M$-5.91M$-34.04M$11.30M

Frequently asked questions

How much free cash flow does CRVS generate?

CRVS produced $-32.97M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CRVS's balance sheet healthy?

CRVS holds $4.58M in cash and equivalents against — in long-term debt, on $61.20M of shareholder equity. That debt is best read against the cash flow the business throws off each year.